By proceeding, you agree to our Terms of Use and Privacy Policy.
Welcome to the 5th Annual Cell Engager Summit! Tecytinib’s approval last year has strongly fuelled the mentality that this is the year of cell engager! Bispecifics have led the way and liquid tumors have been hit hard. Now Immunocore and others are starting to take the fight to solid tumors. The 5th Annual Cell Engager Summit returns this year dedicated to discovering everything there is to know about the immune cell engager landscape, including clinical successes, prospective response predictors, and cutting-edge immune cell-based engager therapeutic discoveries. Join 80+ Cell Engager experts at the most comprehensive 3-day cell engager meeting, leaving no stone unturned, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. Delving into the biggest challenges cell engager therapeutics face including increasing safety and efficacy in the solid tumor microenvironment, targeting tumor antigens, changing co-stimulatory receptors, and maximizing the quality of insights we gain from preclinical modeling.
Learn about translational and clinical challenges of cell engager therapeutics.
Discuss how to optimize drug construct design, maximize potency and efficacy against efficacious tumor targets, and mitigate on-target and off-tumor toxicity.
Demonstrate your experience in a novel immunotherapy laboratory services that integrate scientific knowledge, cutting-edge technology, and industrial connections.
Hear case studies from the successful liquid tumor focussed compounds and identify what key aspects can be transferred to solid tumors to improve overall response rates.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research.
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $1.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.